Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/25/2026 | Q4 | $1.9B | -- | -- | $1.10 | -- |
| 11/04/2025 | Q3 | $1.9B | $2B | $0.57 | $0.96 | -$0.38 |
| 07/24/2025 | Q2 | $2B | $2.2B | $1.18 | $1.02 | $0.16 |
| 05/06/2025 | Q1 | $2.3B | $2.4B | -$0.61 | $1.18 | -$1.79 |
| 02/26/2025 | Q4 | $2.2B | $2.2B | -$0.23 | $1.19 | -$1.42 |
| 11/07/2024 | Q3 | $2.2B | $2.2B | $1.92 | $1.17 | $0.75 |
| 07/30/2024 | Q2 | $2.4B | $2.2B | $1.27 | $1.31 | -$0.04 |
| 05/07/2024 | Q1 | $2.7B | $2.5B | $1.24 | $1.41 | -$0.17 |
| 02/27/2024 | Q4 | $2.9B | $2.8B | $3.11 | $1.92 | $1.19 |
| 11/07/2023 | Q3 | $2.8B | $2.9B | $1.47 | $1.81 | -$0.34 |
| 07/27/2023 | Q2 | -- | $2.4B | $1.34 | -- | -- |
| 05/09/2023 | Q1 | -- | $2.6B | $1.97 | -- | -- |
| 02/27/2023 | Q4 | -- | $3.2B | $5.30 | -- | -- |
| 11/08/2022 | Q3 | -- | $3.7B | $4.63 | -- | -- |
| 08/03/2022 | Q2 | -- | $4B | $5.21 | -- | -- |
| 05/09/2022 | Q1 | -- | $3.4B | -$0.94 | -- | -- |
| 02/24/2022 | Q4 | -- | $3B | $5.19 | -- | -- |
| 11/02/2021 | Q3 | -- | $2.7B | -$0.28 | -- | -- |
| 07/27/2021 | Q2 | -- | $2.5B | -$0.79 | -- | -- |
| 04/28/2021 | Q1 | -- | $2.3B | $1.16 | -- | -- |
| 02/17/2021 | Q4 | -- | $1.6B | -$2.36 | -- | -- |
| 10/28/2020 | Q3 | -- | $1.3B | -$5.85 | -- | -- |
| 07/28/2020 | Q2 | -- | $1B | -$16.87 | -- | -- |
| 05/07/2020 | Q1 | -- | $1.6B | $1.62 | -- | -- |
| 02/19/2020 | Q4 | -- | $1.8B | -$0.02 | -- | -- |
| 10/31/2019 | Q3 | -- | $1.8B | $0.56 | -- | -- |
| 07/31/2019 | Q2 | -- | $1.9B | $1.22 | -- | -- |
| 04/30/2019 | Q1 | -- | $1.6B | -$1.00 | -- | -- |
| 02/28/2019 | Q4 | -- | $1.4B | $5.41 | -- | -- |
| 11/01/2018 | Q3 | -- | $1.5B | $0.20 | -- | -- |
| 08/01/2018 | Q2 | -- | $1.3B | -$0.80 | -- | -- |
| 05/01/2018 | Q1 | -- | $1.3B | $0.80 | -- | -- |
| 02/15/2018 | Q4 | -- | $1.2B | -$1.20 | -- | -- |
| 11/08/2017 | Q3 | -- | $896M | $1.50 | -- | -- |
| 07/21/2017 | Q2 | -- | $954M | $1.70 | -- | -- |
| 05/02/2017 | Q1 | -- | $951M | $2.20 | -- | -- |
| 02/16/2017 | Q4 | -- | $986M | -$1.45 | -- | -- |
| 11/03/2016 | Q3 | -- | $883M | $1.85 | -- | -- |
| 07/21/2016 | Q2 | -- | $694M | -$3.55 | -- | -- |
| 05/03/2016 | Q1 | -- | $630M | -$2.25 | -- | -- |
| 02/24/2016 | Q4 | -- | $828M | -$3.60 | -- | -- |
Ovintiv, Inc. reported $2B worth of top line sales in its most recent quarter.
Ovintiv, Inc. announced earnings per share of $0.57 which represents a miss of analyst forecast a $0.96 per share.
Ovintiv, Inc. reported $538M that represents $2.08 per share over the last quarter.
Ovintiv, Inc.'s earnings are forecast to grow from $4.21 per share to $5.61 per share next year representing an increase of 7.11%.
Ovintiv, Inc.'s next earnings date is February 25, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.